Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26313334 | 0.93 | TMPRSS2 (0.42) | TMPRSS2EGLN2AAK1 | |
| SCHEMBL26206772 | 0.93 | TMPRSS2 (0.42) | TMPRSS2EGLN2AAK1 | |
| SCHEMBL26404508 | 0.88 | TMPRSS2 (0.32) | TMPRSS2EGLN2 | |
| SCHEMBL26319817 | 0.81 | TMPRSS2 (0.39) | TMPRSS2EGLN2 | |
| SCHEMBL26206800 | 0.81 | TMPRSS2 (0.42) | TMPRSS2EGLN2AAK1 | |
| SCHEMBL26206771 | 0.79 | TMPRSS2 (0.65) | TMPRSS2EGLN2AAK1 | |
| SCHEMBL26206362 | 0.79 | TMPRSS2 (0.41) | TMPRSS2EGLN2 | |
| SCHEMBL26326527 | 0.78 | TMPRSS2 (0.56) | TMPRSS2EGLN2AAK1 | |
| SCHEMBL25273133 | 0.76 | TMPRSS2 (0.32) | TMPRSS2 | |
| SCHEMBL30090943 | 0.76 | TMPRSS2 (0.38) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885EGLN2 771/4885AAK1 4644/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885EGLN2 771/4885AAK1 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.